Inventor · disambiguated record
Dennis Verzijl
Also filed as: VERZIJL DENNIS
10 granted patents·16 pending applications·22 citations·filing 2015–2025
86Inventor score
Files withGENMAB AS26
Top patents by PatentIndex Score
26 records- 0191US11008399B2AntibodiesGENMAB AS·Filed 2020·Granted May 18, 2021·2 cites·22 claims
- 0290US10201607B2Antibodies binding AXLGENMAB AS·Filed 2018·Granted Feb 12, 2019·7 cites·28 claims
- 0389US10765743B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Sep 8, 2020·3 cites·46 claims
- 0488US11130819B2AntibodiesGENMAB AS·Filed 2021·Granted Sep 28, 2021·1 cites·30 claims
- 0587US10500276B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Dec 10, 2019·4 cites·35 claims
- 0686US11459395B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2021·Granted Oct 4, 2022·1 cites·19 claims
- 0786US10512688B2Antibodies binding AXLGENMAB AS·Filed 2015·Granted Dec 24, 2019·4 cites·8 claims
- 0885US2024392032A1AntibodiesGENMAB AS·Filed 2024·Application pending·0 cites
- 0979US12410258B2Antibodies capable of binding to OX40, variants thereof and uses thereofGENMAB AS·Filed 2024·Granted Sep 9, 2025·0 cites·23 claims
- 1077US2023087745A1Binding agents binding to pd-l1 and cd137 and use thereofGENMAB AS·Filed 2022·Application pending·0 cites
- 1176US11970544B2AntibodiesGENMAB AS·Filed 2021·Granted Apr 30, 2024·0 cites·31 claims
- 1276US2020171152A1Antibodies binding axlGENMAB AS·Filed 2019·Application pending·0 cites
- 1375US2023321261A1Axl-specific antibody-drug conjugates for cancer treatmentGENMAB AS·Filed 2022·Application pending·0 cites
- 1474US2024317861A1Antibodies against pd-l1GENMAB AS·Filed 2023·Application pending·0 cites
- 1573US11261254B1AntibodiesGENMAB AS·Filed 2021·Granted Mar 1, 2022·0 cites·30 claims
- 1671US2022324980A1AntibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 1771US2025340647A1AntibodiesGENMAB AS·Filed 2025·Application pending·0 cites
- 1868US2020277397A1AntibodiesGENMAB AS·Filed 2020·Application pending·0 cites
- 1967US2021292418A1AntibodiesGENMAB AS·Filed 2021·Application pending·0 cites
- 2065US2020397913A1Axl-specific antibody-drug conjugates for cancer treatmentGENMAB AS·Filed 2020·Application pending·0 cites
- 2163US2025333526A1Antibodies capable of binding to ox40, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 2263US2025333527A1Antibodies capable of binding to ox40, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 2362US2019022243A1Axl-specific antibody-drug conjugates for cancer treatmentGENMAB AS·Filed 2017·Application pending·0 cites
- 2460US2018326084A1Axl-specific antibody-drug conjugates for cancer treatmentGENMAB AS·Filed 2016·Application pending·0 cites
- 2553US2020239579A1Antibodies against pd-l1GENMAB AS·Filed 2018·Application pending·0 cites
- 2650US2023257479A1Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancerGENMAB AS·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Dennis Verzijl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →